People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2010 |
| Nexgel, Inc. | — | Biotechnology | Seed | $4.6M | $37.6M | 2020 |
| Kalytera Therapeutics, Inc. | — | Pharma | Pre-Seed | $2.2M | $35.9M | 2014 |
David Stefansky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Stefansky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerome Zeldis | 3 | 6 |
| Richard Rosenblum | 2 | 6 |
| David Johnson | 1 | 35 |
| Mark Wagner | 1 | 9 |
| James Sapirstein | 1 | 7 |
| Steven Berger | 1 | 7 |
| Kenneth Londoner | 1 | 5 |
| Robert Farrell | 1 | 4 |
| Joseph Sierchio | 1 | 3 |
| Adam Levy | 1 | 3 |
| Brian Posner | 1 | 3 |
| Jeff Paley | 1 | 3 |
| Gary Restani | 1 | 3 |
| Michael M. Goldberg | 1 | 2 |
| Seth Yakatan | 1 | 2 |
| Perry Karsen | 1 | 2 |
| Ronald Erickson | 1 | 2 |
| Benjamin Mayer | 1 | 2 |
| Joseph M. Leone | 1 | 1 |
| Joseph C. Sierchio | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.